以岭药业(002603) - 2018 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2018 was CNY 1,580,599,501.69, representing a 20.23% increase compared to CNY 1,314,670,178.75 in the same period last year[8]. - Net profit attributable to shareholders was CNY 310,663,574.03, up 41.55% from CNY 219,480,098.00 year-over-year[8]. - The basic earnings per share increased by 35.71% to CNY 0.2527 from CNY 0.1862 in the previous year[8]. - The company expects net profit attributable to shareholders for the first half of 2018 to increase by 25.00% to 35.00%, ranging from ¥42,410.71 to ¥45,803.57 million[18]. Assets and Shareholder Equity - The company's total assets at the end of the reporting period were CNY 8,191,149,489.94, a 3.85% increase from CNY 7,887,369,191.32 at the end of the previous year[8]. - The net assets attributable to shareholders rose by 4.51% to CNY 7,431,044,754.93 from CNY 7,110,187,472.49[8]. - The total number of ordinary shareholders at the end of the reporting period was 42,501[10]. - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., held 23.75% of the shares, amounting to 286,276,398 shares[11]. Cash Flow - The net cash flow from operating activities was negative at CNY -154,350,991.65, worsening by 46.31% compared to CNY -105,499,199.37 in the same period last year[8]. - The net cash flow from operating activities decreased by 46.31% to -¥154,350,991.65, as revenue growth was outpaced by operating cash expenditures[15]. - The net cash flow from investing activities improved by 207.93% to ¥41,772,876.27, attributed to reduced cash outflows for external investments[15]. Receivables and Prepayments - Accounts receivable increased by 46.54% to ¥1,009,087,871.56 due to expanded sales scale and increased customer credit[15]. - Prepayments increased by 42.34% to ¥131,821,350.32, resulting from higher operating activity expenditures[15]. - The company recorded a 30.09% decrease in advance receipts to ¥69,969,740.16, as pre-collection of customer payments declined[15]. Other Financial Metrics - The weighted average return on equity increased to 4.26%, up from 3.48% in the previous year[8]. - The company reported non-recurring gains and losses totaling CNY 2,431,711.62 for the period[9]. - Investment income surged by 1522.92% to ¥8,425,473.78, driven by increased returns from bank and fund products[15]. - Financial expenses decreased by 91.46% to -¥2,453,681.43, due to a rise in interest income[15]. - The company reported a 76.77% increase in business taxes and additional fees to ¥35,660,492.80, primarily due to increased urban construction education fees[15]. - Other non-current assets rose by 82.57% to ¥75,002,356.00, reflecting an increase in prepaid long-term assets[15].